Ionis Pharmaceuticals IONS Short-Term Borrowings
Short-Term Borrowings at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleDebtCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's short-term borrowings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's short-term borrowings?
- Ionis Pharmaceuticals (IONS) reported short-term borrowings of $432.5M in Q1 2026.
- What is the long-term trend for Ionis Pharmaceuticals's short-term borrowings?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's short-term borrowings has grown at a 6.9% compound annual growth rate (CAGR), from $308.81M to $431.95M.
- What does short-term borrowings mean?
- The total amount of debt that must be paid back within one year.
- How do you interpret short-term borrowings?
- An increase may indicate a need for liquidity or aggressive working capital management, while a decrease suggests debt repayment or reliance on alternative funding sources.
- How does short-term borrowings compare across companies?
- Varies significantly based on the company's stage of drug development and access to capital markets.